Navigation Links
SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia
Date:12/8/2008

DUBLIN, Calif., Dec. 8/PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that its oral PIM kinase inhibitor, SGI-1776, is effective both in vitro and in vivo in preclinical models of acute lymphoblastic leukemia (ALL) (Abstract #1922). This research was presented at the 50th Annual Meeting of the American Society of Hematology.

In a poster presentation entitled "Inhibiting PIM-1 is effective in vitro and in vivo against ALL: A novel mechanistic and potentially clinically relevant druggable target," Dr. Valerie Brown and colleagues from Children's Hospital of Philadelphia and University of Pennsylvania demonstrated that SGI-1776 inhibited human ALL cell lines in a dose-dependent manner. Furthermore, SGI-1776 and the m-tor inhibitor rapamycin acted synergistically to inhibit ALL cell proliferation. In a clinically relevant in vivo model, NOD/SCID mice xenografted with human primary ALL cells, SGI-1776 also reduced tumor burden.

"Our PIM kinase inhibitor, SGI-1776, has significant potential in hematologic malignancies," commented Dr. Gregory Berk, Chief Medical Officer of SuperGen. "PIM-1 is known to be overexpressed in ALL, AML, CML, as well as non-Hodgkin's lymphoma. In many of these conditions PIM-1 overexpression is a poor prognostic factor. It has been postulated that inhibition of PIM kinase may potentiate the activity of m-tor inhibitors by modulation of m-tor inhibitor resistance pathways. These elegant preclinical experiments by Dr. Brown and her colleagues at the University of Pennsylvania support this hypothesis."

SuperGen recently received clearance for a phase I trial with SGI-1776 in patients with non-Hodgkin's lymphoma and prostate cancer, and plans to initiate a second phase I trial of SGI-1776 in patients with relapsed/refractory leukemias in 2009.

Copies of the poster presentations at the ASH Annual Meeting are available in the pipeline section of SuperGen's Web site www.supergen.com.

About SGI-1776

SGI-1776 inhibits the three human PIM kinases (PIM-1, PIM-2 and PIM-3). PIM kinases are highly conserved serine-threonine kinases that are key regulators in many signaling pathways implicated in cancer. When expressed, PIM kinases are strong survival factors and can induce progression of the cell cycle, inhibition of apoptosis, and modulation of other signal transduction pathways. Therefore, SGI-1776 can induce cell death in cancer cells expressing PIM kinases and promote sensitivity of cancer cells to treatment with other targeted and chemotherapy drugs. SGI-1776 has broad potential as a single agent as well as in combination with other agents, as PIM kinases contribute to many malignancies including prostate adenocarcinomas, diffuse large cell lymphomas, as well as several types of leukemias.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. SuperGen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For more information about SuperGen, please visit www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause the company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability to discover, develop and move target compounds into clinical development and other risks and uncertainties detailed from time to time in the company's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no duty to update any of these forward-looking statements to conform them to actual results.

    Contacts
    Timothy L. Enns
    SuperGen, Inc.
    SVP, Corporate Communications & Business Development
    Tel: (925) 560-2810
    E-mail: tenns@supergen.com

    Michael Beckerich
    Dorland Global Public Relations
    Media
    Tel:  (212) 677-7632
    mbeckerich@dorland.com


'/>"/>
SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
2. Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors
3. SuperGens PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models
4. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
5. Latest Cell Publication Describes the Novel Kinase Regulators Using OriGenes Functional Kinome Collection
6. SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
9. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
10. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
11. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland ... iHire in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness ... & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):